Amyloid beta-protein oligomer (Aβ oligomer (or AβO))

Amyloid beta-protein oligomer (Aβ oligomer or AβO) refers to soluble assemblies of the amyloid beta (Aβ) peptide, typically comprised of a few (2–20) Aβ monomers. These peptide aggregates form spontaneously from Aβ monomers, which are 38–43 amino acids in length and produced by proteolytic cleavage of amyloid precursor protein (APP)[1][3][5][7]. Unlike insoluble fibrils that form amyloid plaques, Aβ oligomers are soluble, metastable, and especially neurotoxic. They adopt beta sheet-rich quaternary structures that disrupt cell membranes, interfere with synaptic function, induce mitochondrial dysfunction, activate inflammatory pathways, and impair neuronal viability[2][3][5][9]. Strong evidence implicates Aβ oligomers as central toxins in Alzheimer’s disease (AD) pathogenesis, playing critical roles in synaptic dysfunction, memory impairment, and neurodegeneration[2][4][8]. Therapeutic interventions increasingly focus on neutralizing Aβ oligomers with monoclonal antibodies (e.g., lecanemab, aducanumab), nanoparticle-based inhibitors, or immunomodulation rather than targeting mature amyloid plaques[2][4][6]. Drug development is challenged by their transient, heterogeneous structure, need for selective detection, and risks of inflammatory adverse effects associated with immunotherapies[2][4][6].

Other names

amyloid-β oligomerbeta-amyloid oligomerAβ oligomeramyloid beta oligomerAβOamyloid beta-protein oligomers

Direct neutralization of oligomers by antibody binding; Promotion of oligomer clearance via immune mechanisms; Disruption or inhibition of oligomer assembly or aggregation; Inhibition of oligomer toxicity at neuronal synapses; Inhibition of AβO nucleation (nanoparticle-mediated); Reduction of beta-amyloid burden via immune-mediated phagocytosis